Cargando…
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524676/ https://www.ncbi.nlm.nih.gov/pubmed/33028485 http://dx.doi.org/10.1016/j.bbrc.2020.09.128 |
_version_ | 1783588590268186624 |
---|---|
author | Carafoli, Ernesto |
author_facet | Carafoli, Ernesto |
author_sort | Carafoli, Ernesto |
collection | PubMed |
description | At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it. |
format | Online Article Text |
id | pubmed-7524676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75246762020-09-30 Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection Carafoli, Ernesto Biochem Biophys Res Commun Article At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it. Published by Elsevier Inc. 2021-01-29 2020-09-30 /pmc/articles/PMC7524676/ /pubmed/33028485 http://dx.doi.org/10.1016/j.bbrc.2020.09.128 Text en © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Carafoli, Ernesto Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title_full | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title_fullStr | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title_full_unstemmed | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title_short | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection |
title_sort | chloroquine and hydroxychloroquine in the prophylaxis and therapy of covid-19 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524676/ https://www.ncbi.nlm.nih.gov/pubmed/33028485 http://dx.doi.org/10.1016/j.bbrc.2020.09.128 |
work_keys_str_mv | AT carafoliernesto chloroquineandhydroxychloroquineintheprophylaxisandtherapyofcovid19infection |